Drug Disposition & Biological Products

Pharmacokinetic studies are more important for therapeutic biologics . Identifying the key factors that govern absorption, distribution, metabolism,  and excretion of biologics as therapeutic agents improved the opportunities for the scientists working in drug disposition research field.

The European Union (EU) first approved a biologic in 2006, now there are more than 700 biosimilars approved or in the pipeline globally. Analysts expect the worldwide biosimilars market to reach $25 billion to $35 billion by 2020. Generics have larger share of total global medicine spend, increasing from 27 percent ($261 billion) in 2012 to 36 percent ($421 billion) by 2017.

  • Drug Absorption Methods
  • Effect of pH on Drug Disposition
  • Drug Distribution
  • Drug Metabolism
  • Drug Excretion
  • Biologics and Biosimilars
  • Buffers in Biologics Manufacturing

Related Conference of Drug Disposition & Biological Products

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson, Toronto, Canada
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15, 2018

13th International Conference on Biosimilars and Biologics

Lisbon, Portugal
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Drug Disposition & Biological Products Conference Speakers

Recommended Sessions

Related Journals

Are you interested in